As manufacturers invest in clinical development of rare disease therapies, payers are examining disease prevalence estimates and determining reimbursements. In this article published in Life Science Leader, Cécile Matthews, Bhavesh Patel, and Owen Male discuss factors payers are considering for such reimbursements. The authors recently conducted an analysis of 15 rare and ultra-rare disease therapies recently approved in France, Germany, Italy, Spain, the UK, and Japan to better understand the factors payers are now considering for reimbursement of rare disease drugs.
Click here to read the article.
Review: Clinical Considerations & Payer Perspectives
Late October saw the annual gathering of oncologists and industry in Madrid for ESMO 2023, bringing with it a wave of new clinical results across cancers and a...